Recent clinical studies have shown that SGLT-2 inhibitors significantly reduce the hospitalization rates for heart failure and the risk of cardiovascular death in CKD patients, while effectively managing metabolic diseases like obesity and hyperuricemia (136). The gene discussed is SLC5A2; the disease is obesity disorder.